Metformin approval history
Pro Research Analysisby 
Searched over 400M research papers
Early Development and European Approval of Metformin
Metformin’s origins trace back to the plant Galega officinalis, used in traditional European medicine for its blood sugar-lowering properties. The active component, guanidine, inspired the synthesis of biguanides, including metformin, in the early 20th century. While other biguanides were used in the 1920s and 1930s, they were discontinued due to toxicity concerns and the rise of insulin therapy. Metformin itself was first identified as a potential antidiabetic agent in the 1940s and was introduced for diabetes treatment by French physician Jean Sterne in 1957. However, it initially received limited attention because it was considered less potent than other biguanides, which were later withdrawn due to safety issues, particularly lactic acidosis risks Bailey2017Liu2023Zapasek2024.
U.S. FDA Approval and Regulatory Changes
Metformin’s journey to U.S. approval was cautious due to its association with other, riskier biguanides. After extensive evaluation, the U.S. Food and Drug Administration (FDA) approved metformin in 1994 (with some sources noting 1995) as a treatment for type 2 diabetes. At the time of approval, the FDA included a boxed warning about the risk of lactic acidosis, especially in patients with chronic kidney disease (CKD), congestive heart failure (CHF), or chronic liver disease (CLD) Bailey2017Crowley2017Ravindran2017.
Over time, accumulating evidence showed that metformin was safer than previously thought, especially compared to other biguanides. In 2006, the FDA removed CHF as a strict contraindication, and in 2016, it updated its guidance to allow metformin use in patients with moderate CKD, expanding eligibility to more patients. Severe CKD remains a contraindication Crowley2017Ravindran2017.
Extended-Release Formulations and Recent Approvals
Metformin’s formulations have evolved, with the FDA approving an extended-release oral suspension (Riomet ER) in August 2019. This formulation offers an alternative for patients who have difficulty swallowing tablets and aligns with the American Diabetes Association’s recommendation of metformin as the preferred initial therapy for type 2 diabetes .
Ongoing Safety and Quality Concerns
Despite its long history and widespread use, metformin has faced recent scrutiny over impurities. The FDA has identified N-nitrosodimethylamine (NDMA), a potential carcinogen, in some metformin products, leading to recalls and ongoing monitoring to ensure product safety .
Expanding Clinical Applications
Metformin’s approval history is also marked by its expanding use beyond diabetes. It is now recommended for conditions like obesity and polycystic ovary syndrome (PCOS), and research continues into its potential benefits for cardiovascular protection, cancer prevention, and other metabolic disorders Liu2023Zapasek2024.
Conclusion
Metformin’s approval history reflects a cautious but ultimately successful journey from herbal remedy to the world’s most prescribed glucose-lowering medication. Regulatory agencies have adapted their guidance as evidence has accumulated, broadening metformin’s use while maintaining safety standards. Today, metformin remains a cornerstone of diabetes care and continues to find new therapeutic roles in medicine Satterwhite2021Bailey2017Crowley2017+3 more.
Sources and full results
Most relevant research papers on this topic